We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesQuoin Pharmaceuticals Ltd DRC

Quoin Pharmaceuticals Ltd DRC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.74 USD -0.02 ( 0.53%)
Last update at 2026-11-12T15:40:00Z
VOLUME
4651
Market Cap
2.87M

Momentum Score

…

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.74
Low
3.83
High
52 Week Price Range
0.60
Low
12.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Quoin Pharmaceuticals Ltd DRC is a Nasdaq-listed development-stage pharmaceutical company with limited public disclosures about its pipeline and operations. Long-term growth could be driven by clinical progress, regulatory approvals, strategic partnerships and successful capital raises. Investors may find potential upside if development programs advance toward commercialization.

Key risks include a high probability of clinical or regulatory setbacks, recurring financing needs that may dilute shareholders, thin trading liquidity and operational execution challenges common to small biotechs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.76
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-132.92%
Net Debt
-2.40M
ROCE
-103.04%
Diluted EPS TTM
-6.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -9.38M -21.46M -2.10M -1.56M 15.32M
Net income -9.28M -8.52M -1.76M -1.56M 15.32M
Selling general administrative 6.58M 4.50M 1.43M 1.51M 7.97M
Gross profit - - - - -0.28M
Reconciled depreciation 0.10M 0.10M 0.10M 0.02M -
Ebit -8.85M -20.37M -2.05M -1.56M -
Ebitda -8.74M -20.27M -1.94M -1.54M 15.32M
Depreciation and amortization 0.10M 0.10M 0.10M 0.02M -
Operating income -8.85M -20.37M -2.05M -1.56M 15.32M
Other operating expenses 9.26M 6.06M 1.67M 1.56M 16.22M
Interest expense 0.71M 1.09M 0.05M 0.00M -
Interest income 0.10M - - - -
Net interest income -0.62M -1.37M -0.05M 0.00M -
Income tax expense -0.10M -12.94M -0.33M - -
Total revenue 0.00M 0.00M 0.00M 0.00M -0.28M
Total operating expenses 9.26M 6.06M 1.67M 1.56M 16.22M
Total other income expense net -0.53M -1.09M -0.05M - -
Net income from continuing ops -9.38M -21.46M -2.10M -1.56M -
Net income applicable to common shares -9.45M -21.46M -2.10M -1.56M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 12.17M 14.46M 9.36M 1.38M 21.32M
Intangible assets 0.58M 0.70M 0.81M 0.91M -
Other current assets 0.59M 0.52M 1015.47M 0.14M -
Total liab 6.51M 7.05M 8.70M 7.99M 0.40M
Total stockholder equity 5.66M 7.41M 0.66M -6.61M -
Other current liab 3.05M 2.92M 7.78M 6.77M 1.88M
Common stock - -2932.00M 31.66M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M -
Retained earnings -46.20M -37.52M -28.07M -6.61M -100.86M
Other liab - - 0.37M - -
Other assets - 0.38M 0.05M - 0.89M
Cash 2.40M 2.86M 7.48M 0.32M 18.11M
Total current liabilities 3.58M 3.53M 8.70M 7.99M 0.40M
Current deferred revenue -0.00M - -743.84M - -
Net debt -2.40M -2.86M 736.36M 0.89M -17.71M
Short term debt 0.00M - 743.84M 1.21M 0.40M
Short long term debt - - - 1.21M -
Short long term debt total 0.00M - 743.84M 1.21M 0.40M
Other stockholder equity 51.87M 2976.92M 28.73M 0.00M 100.86M
Total current assets 11.29M 13.37M 8.50M 0.47M 18.11M
Net tangible assets - 6.70M -0.15M -7.52M -5.53M
Short term investments 8.29M 9.99M - - -
Accounts payable 0.53M 0.61M 0.92M 0.00M -
Accumulated other comprehensive income 0.00M - - - -
Non currrent assets other 0.30M 0.38M 0.05M -1.94M -
Non current assets total 0.88M 1.09M 0.86M 0.91M 2.32M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.46M -10.15M -0.62M -0.12M -9.90M
Change to liabilities - -0.22M 1.35M 0.23M 0.24M
Total cashflows from investing activities - -10.15M -0.62M -0.12M -0.12M
Net borrowings - -0.91M 3.31M 1.93M 1.30M
Total cash from financing activities 5.22M 14.01M 13.50M 1.79M 1.30M
Change to operating activities - 0.12M -0.02M 0.05M 0.05M
Net income -8.66M -9.38M -21.46M -2.10M -1.56M
Change in cash -0.46M -4.62M 7.16M -4.92M 5.24M
Begin period cash flow 2.86M 7.48M 0.32M 5.24M 0.00M
End period cash flow 2.40M 2.86M 7.48M 0.32M 5.24M
Total cash from operating activities -7.84M -8.48M -5.72M -1.34M -1.30M
Depreciation 0.10M 0.10M 0.10M 0.10M 0.02M
Other cashflows from investing activities - -0.25M -0.62M -0.12M -0.12M
Dividends paid - 65.27M - - -
Change to inventory - - - -0.06M 0.36M
Change to account receivables - - - 0.06M 0.11M
Sale purchase of stock - -14.82M - - -
Other cashflows from financing activities 5.22M 79.59M 6.87M 1.79M -4.84M
Change to netincome - 0.89M 14.03M 0.38M 0.38M
Capital expenditures 0.00M 0.25M 0.62M 0.12M 0.12M
Change in working capital 0.10M -0.09M 1.33M 0.27M 0.24M
Stock based compensation 1.09M 0.76M 0.00M - -
Other non cash items 53.45M 0.13M 14.31M 0.38M -0.51M
Free cash flow -7.84M -8.73M -6.35M -1.46M -1.42M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
QNRX
Quoin Pharmaceuticals Ltd DRC		 -0.02
0.53%		 3.74 - - - 0.48 -0.42
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Quoin Pharmaceuticals Ltd DRC

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349

703 980 4182

https://quoinpharma.com

4

Name Title Year Born
Dr. Michael Myers Ph.D. Co-Founder, CEO & Chairman 1962
Ms. Denise Carter Co-Founder, COO & Director 1969
Mr. Gordon Bruce Dunn J.D. Chief Financial Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…